Red Dye 40 vs Recombinant Bovine Growth Hormone: which is worse?

What is Red Dye 40?

Red Dye 40 (Allura Red AC) is a synthetic petroleum-derived azo dye that produces a bright red-orange color. It belongs to the monoazo chemical class and is highly water-soluble, with the formula C18H14N2Na2O8S2. It replaced amaranth (Red Dye 2), which was banned in the US in 1976 following cancer concerns.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Red Dye 40: Red Dye 40 has been linked to several health concerns, particularly in children. The most documented association is with hyperactivity and ADHD-related behavior. A landmark 2007 study in The Lancet (McCann et al.) found that a mixture of six artificial dyes including Red 40, combined with sodium benzoate, significantly increased hyperactivity scores in children ages 3 and 8–9. This prompted EFSA to require the 'may have adverse effect on activity and attention in children' warning label across the EU and UK. A 2012 meta-analysis in Neurotherapeutics (Arnold et al.) confirmed a small but statistically significant deleterious effect of artificial food colors on children's behavior, even in those without diagnosed ADHD. The authors described the effect as a public health issue rather than merely an ADHD issue. Regarding carcinogenicity: commercial batches of Red 40 contain trace amounts of benzidine, an IARC Group 1 human carcinogen. A 1994 study in Food and Chemical Toxicology documented benzidine contamination. The FDA maintains that exposure is below harmful thresholds, but the Center for Science in the Public Interest (CSPI) has cited this contamination in multiple ban petitions. Allergic reactions are documented: Red 40 can trigger histamine release leading to hives, rhinitis, and in rare cases anaphylaxis. Cross-reactivity with aspirin is established in aspirin-sensitive individuals. Gut health: A 2021 study in Nature Communications (Kwon et al.) found Red 40 may worsen inflammatory bowel disease and induce colitis-like symptoms in genetically susceptible mice by triggering immune responses in gut-associated lymphoid tissue. In April 2025, HHS Secretary RFK Jr. announced the FDA would phase out Red 40 and 7 other petroleum-based dyes from the US food supply.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.